Keywords: Seattle Genetics, Adcetris, sBLA, Hodgkin lymphoma, Systemic ALCL, USA, FDA

Seattle Genetics files sBLA for Adcetris in relapsed Hodgkin lymphoma and systemic ALCL

Article | 19 March 2013

Print This

US biotech firm Seattle Genetics (Nasdaq: SGEN) has submitted a supplemental Biologics License Application (sBLA) to the US Food and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in